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Abstract
Background: Angiogenesis plays an important role in a wide range of physiological processes, and many diseases are
associated with the dysregulation of angiogenesis. Radix Astragali is a Chinese medicinal herb commonly used for treating
cardiovascular disorders and has been shown to possess angiogenic effect in previous studies but its active constituent and
underlying mechanism remain unclear. The present study investigates the angiogenic effects of calycosin, a major
isoflavonoid isolated from Radix Astragali, in vitro and in vivo.
Methodology: Tg(fli1:EGFP) and Tg(fli1:nEGFP) transgenic zebrafish embryos were treated with different concentrations of
calycosin (10, 30, 100 mM) from 72 hpf to 96 hpf prior morphological observation and angiogenesis phenotypes
assessment. Zebrafish embryos were exposed to calycosin (10, 100 mM) from 72 hpf to 78 hpf before gene-expression
analysis. The effects of VEGFR tyrosine kinase inhibitor on calycosin-induced angiogenesis were studied using 72 hpf
Tg(fli1:EGFP) and Tg(fli1:nEGFP) zebrafish embryos. The pro-angiogenic effects of calycosin were compared with raloxifene
and tamoxifen in 72 hpf Tg(fli1:EGFP) zebrafish embryos. The binding affinities of calycosin to estrogen receptors (ERs) were
evaluated by cell-free and cell-based estrogen receptor binding assays. Human umbilical vein endothelial cell cultures
(HUVEC) were pretreated with different concentrations of calycosin (3, 10, 30, 100 mM) for 48 h then tested for cell viability
and tube formation. The role of MAPK signaling in calycosin-induced angiogenesis was evaluated using western blotting.
Conclusion: Calycosin was shown to induce angiogenesis in human umbilical vein endothelial cell cultures (HUVEC) in vitro
and zebrafish embryos in vivo via the up-regulation of vascular endothelial growth factor (VEGF), VEGFR1 and VEGFR2 mRNA
expression. It was demonstrated that calycosin acted similar to other selective estrogen receptor modulators (SERMs), such
as raloxifene and tamoxifen, by displaying selective potency and affinity to estrogen receptors ERa and ERb. Our results
further indicated that calycosin promotes angiogenesis via activation of MAPK with the involvement of ERK1/2 and ER.
Together, this study revealed, for the first time, that calycosin acts as a selective estrogen receptor modulator (SERM) to
promote angiogenesis, at least in part through VEGF-VEGFR2 and MAPK signaling pathways.
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Introduction
Angiogenesis is the establishment of the mature blood vessel
network through expansion and remodeling of the pre-existing
vascular primordium. Blood vessel formation through angiogenesis
involves the induction of new sprouts, coordinated and directed
endothelial cell migration, proliferation, sprout fusion (anastomo-
sis) and lumen formation [1]. It is a process tightly regulated by a
variety of pro-angiogenic factors such as the estrogen receptors
(ERs). ERs are a group of transcriptional factors that belong to the
nuclear receptor superfamily and are activated by estrogen. In
addition to its reproductive function, ER also plays an important
role in the cardiovascular system [2]. Previous studies have
demonstrated that ER expressed in endothelial cells mediates
angiogenesis through both classical genomic, and rapid non-
genomic, mechanisms [3,4,5]. Ligands of ER such as 17b-estradiol
(E2), estradiol and raloxifene have been shown to induce
endothelial cells proliferation and migration [6,7]. Meanwhile,
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some isoflavonoids possessing estrogenic properties that are
regarded as selective estrogen receptor modulators (SERMs), also
provide cardiovascular benefits, including regulation of endothelial
cells proliferation, differentiation, adhesion, migration and kinase
activation through interacting with ER [8,9].
Natural products, such as certain Chinese medicines, contain a
variety of angiogenic compounds. It has been demonstrated that
Rg1 and Rb1, the two prevalent saponins of Ginseng, have opposing
effects in modulating angiogenesis [10]. Another Chinese medicine
Radix Astragali, which is rich in isoflavonids, is often used either as a
single herb or in combination with other Chinese medicines as
formula for treating myocarditis [11], heart failure [12], myocardial
infarction [13], pulmonary hypertension [14,15,16,17], chronic
hepatitis [18], diabetes [19,20] and systemic lupus erythematosus
[21] among others. Danggui buxue tang (DBT), a Chinese herbal
concoction composed of Radix Astragali and Angelica sinensis, is
commonly prescribed to treat menopausal irregularity and
menstrual disorders [22,23,24]. DBT triggered specific phosphor-
ylations of ERa and ERK1/2 in the cultured human breast cancer
cell line, MCF-7 [25].
Despite Radix Astragali have been shown to stimulate angiogen-
esis in some studies, the mechanism underlying its angiogenic
activity remains unclear [26]. The major bioactive constituents of
Radix Astragali are saponins and flavonoids, including astragaloside
(I,VIII), calycosin, formononetin, ononin and their glucosides
[27,28]. Among these isoflavonoids, calycosin is the candidate with
most potential to develop as a small-molecule angiogenic agent,
due to its benefits upon endothelial cells [29]. Calycosin protects
HUVECs from hypoxia-induced barrier impairment by increasing
intracellular energetic sources and promoting regeneration of
cAMP levels, as well as improving cytoskeleton remodeling. Our
previous study illustrated that Radix Astragali extract (RAE)
possesses pro-angiogenic effects upon human umbilical vein
endothelial cells (HUVECs), which involve the VEGF-VEGFR2
and PI3K-Akt-eNOS pathways [30]. HPLC chromatography
revealed that the compositions of formononetin, calycosin, (6aR,
11aR)-9,10-dimethoxy-3-hydroxypterocarpan and saponins (astra-
galoside I, II and IV) in the RAE were 8.15%, 0.77%, 0.01% and
0.88% of the whole extract, respectively. In regards to the
preliminary screening of the angiogenic effects of these constitu-
ents, calycosin was found to be the most potent pro-angiogenic
agent among all. This present study examines whether calycosin
acts on ER and promotes angiogenesis in HUVEC cultures in vitro
and a transgenic zebrafish model in vivo.
Results
Pro-angiogenic effect of calycosin in zebrafish
In zebrafish, angiogenic vessel development does not begin until
20 hpf (hours-post fertilization), and changes in subintestinal vein
vessels (SIVs) are detected after 72 hpf. Fig. 1A shows that the
SIVs of Tg(fli1:EGFP) zebrafish line treated with 0.1% DMSO at
96 hpf developed as a smooth basket-like structure. Following
calycosin treatment (10, 30, 100 mM) from 72 hpf to 96 hpf, the
diameter of SIVs increased in a dose-dependent manner (Fig. 1B–
D). Quantitative analysis confirmed a significant (P,0.05 and
P,0.001) dose-dependent effect of calycosin on diameter of SIVs
compared with the control group (Fig. 1E).
In order to determine whether the change of blood vessel
phenotype (Fig. 1B–D) involves merely a transient vasodilation
effect, or genomic action on stimulating endothelial cells
proliferation, Tg(fli1:nEGFP) zebrafish embryos were used to
demonstrate the angiogenic effect of calycosin. Tg(fli1:nEGFP) fish
were engineered similarly to Tg(fli1:EGFP) except that Tg(fli1:
nEGFP) harbor nuclear-localized GFP expression, permitting real-
time in vivo analysis of individual endothelial cells [31]. These
results show that calycosin treated (10, 30, 100 mM) SIVs
contained significantly (P,0.01 and P,0.001) more endothelial
cells (Fig. 2B–D) throughout the SIV region than the control group
(Fig. 2A). Quantitative analysis indicates that calycosin induced an
approximately 1.5 times increase in endothelial cells population
compared with the control (Fig 2E).
Detection of mRNA expression in calycosin treated
zebrafish
In order to identify molecular targets of the angiogenic effects of
calycosin in zebrafish, mRNAs from different groups were isolated
and reverse transcribed to cDNA, and relative gene expression
determined using real-time PCR. VEGFA is a fundamental
mediator of physiological and pathophysiological angiogenesis
[32], and acts through tyrosine kinase receptors. VEGFR2 (fetal
liver kinase, also known as KDR and Flk-1) has a higher affinity
for VEGF and is a major transducer of the VEGF signal in
endothelial cells [33,34].
The bar charts in Fig. 3 represent the gene expression of
VEGFA after treatment with 100 mM calycosin for 6 h. There was
an increase trend of mRNA expression level compared to the
control (1.2-fold at 100 mM), and calycosin caused a significant
increase in mRNA expression of VEGFR1 (1.1-fold at 100 mM;
P,0.001), Flk1A (0.8-fold at 100 mM; P,0.001) and Flk1B (0.9-
fold at 100 mM; P,0.001). Hence, these results suggest that the
up-regulation of expression of these genes caused by calycosin
could contribute to the pro-angiogenic effects of calycosin
observed in zebrafish.
VEGFRs are important in calycosin-induced angiogenic
effects
VEGFR tyrosine kinase inhibitor II (VTKI, VRI), a pyridinyl-
anthranilamide compound that displays both antiangiogenic and
antitumor properties, has been shown to potently inhibit the kinase
activities of VEGFR1 and VEGFR2 [35]. We found that VRI,
when in high concentration (1 mg/ml), caused significant
(P,0.001) defects in angiogenesis in zebrafish embryonic devel-
opment (Fig. 4E). Indeed, a lower concentration of VRI (100 ng/
ml), which itself had no effect (Fig. 4C), caused significant
(P,0.001) defects in calycosin-induced angiogenesis in zebrafish
embryonic development (Fig. 4D). Quantitative analysis confirmed
that a low concentration of VRI (100 ng/ml) was sufficient to
reverse the calycosin-induced angiogenic effects to control levels
(Fig. 4F & 4G). This indicates that, in exerting its effect, calycosin
interacts with VEGF receptors (VEGFRs), further confirming that
calycosin-induced angiogenesis, at least in part, involves the
VEGF- VEGFR2 signaling pathway.
Calycosin acts directly but differentially with ERa and ERb
Since ERs are potential targets of calycosin [25], its binding
affinities to ERa and ERb were evaluated by fluorescent
polarization competitive binding assay. 17-b-estradiol (E2), a native
agonist for both ERa and ERb, was used as a positive control. In
this study, E2 displayed strong binding affinity for ERa and ERb
(ERa: IC50= 2.086 nM, Fig. 5A–i; ERb: IC50= 1.484 nM, Fig. 5A–
ii). Calycosin displaced FluormoneTM ES2 and bound to ERa and
ERb in a dose-dependent manner (Fig. 5A–i & Fig. 5A–ii). The
binding affinities of calycosin to ERa and ERb were not as strong as
that of E2, with an IC50 value approximately 10
4-fold higher than
that of E2 and its lower maximum displacement. On the other
hand, the IC50 value of calycosin at ERa (IC50= 58.123 mM,
Calycosin is Pro-Angiogenic
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Fig. 5A–i) was very similar to that at ERb (IC50= 32.428 mM,
Fig. 5A–ii).
To further examine the transcriptional agonistic/antagonistic
action of calycosin on ERs, GeneBLAzer b-lactamase reporter-
gene experiments were performed. Calycosin showed weak
agonistic activities at both ERa and ERb (maximum activity was
14.6% and 8.6%, respectively, Fig. 5B–i). In contrast, the
antagonistic activities of calycosin against E2 at ERa and ERb
Figure 1. The effects of calycosin treatment on blood vessel formation in SIVs of Tg(fli1:EGFP) zebrafish embryos. (A) Control: embryo
treated with 0.1% DMSO at 96 hpf, SIVs appear as a smooth basket-like structure. (B–D) Calycosin: embryo treated with 10, 30, 100 mM calycosin at
72 hpf for 24 h, leads to enlarged SIV basket stretching into the posterior yolk extension. (a–d) Enlarged SIV region (64.5) of A–D respectively. White
arrows indicating the enlarged vessels, yellow and red arrows indicate sprouting and intersectioning branches respectively. (E) Calycosin increases SIV
diameter in a dose-dependent manner. Data are plotted as mean6SEM, (n = 3), *P,0.05, #P,0.001.
doi:10.1371/journal.pone.0011822.g001
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were significant (maximum inhibition was 46% and 82%,
respectively; P,0.01; Fig. 5B–ii). Thus, our results suggest that
calycosin is a partial agonist/antagonist for both ERa and ERb.
Calycosin also displayed receptor-selective potency and efficacy in
the reporter gene assay. In the agonist activity assay, calycosin
showed ERa selectivity with a 2-fold reduction in EC50 value and a
2-fold increase in maximal activation compared with ERb (Fig. 5B–
i). However, calycosin was more potent and efficacious at ERb than
at ERa in the antagonist activity assay, showing a 2-fold reduction in
IC50 value and a 2-fold increase in maximal inhibition (Fig. 5B–ii).
Figure 2. The effects of calycosin on endothelial cells population in SIVs of Tg(fli1:nEGFP) zebrafish embryos. Each green light point
represents one endothelial cell (GFP+). (A) Control: embryo treated with 0.1% DMSO at 96 hpf. (B–D) Calycosin: embryo treated with 10, 30, 100 mM
calycosin at 72 hpf for 24 h, leads to an increase in endothelial cells. (a–d) Enlarged SIV region (64.5) of A–D respectively. (E) Calycosin increases the
number of endothelial cells in the SIV region in a dose-dependent manner. Data are plotted as mean6SEM, (n = 3), **P,0.01, #P,0.001.
doi:10.1371/journal.pone.0011822.g002
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Comparison of angiogenic effects of calycosin with other
classical SERMs in zebrafish embryos.
Raloxifene is a SERM approved for clinical use in osteoporosis,
and has been suggested to induce cardioprotection in women at
high risk of coronary heart disease [36]. Another example of a
SERM is tamoxifen, which is an antagonist of the estrogen
receptor and is used in treating breast cancer [37]. E2 represents
the major estrogen in humans, which modulates various vascular
functions, including inflammation, wound healing, and angiogen-
esis [38,39,40]. As shown in Fig. 6, only calycosin exhibited a
significant angiogenic effect in SIVs (Fig. 6e, thick arrow), while no
obvious changes were observed in the raloxifene (10 mM),
tamoxifen (3 mM) and 17-bEstradiol (10 mM) groups (Fig. 6b–d,
arrows) at their highest non-toxic doses in zebrafish embryos.
Calycosin promotes angiogenesis in HUVEC in vitro
The effect of calycosin on HUVEC proliferation was evaluated
using an XTT assay. Following a 24 h starvation, HUVECs were
cultured in low serum medium supplemented with calycosin
(1 mM–100 mM; 48 h). Cell viability was estimated by determining
the amount of formazon product formed in the cell culture
medium. As shown in Fig. 7A, calycosin promoted cell
proliferation in a dose-dependent manner. The maximum increase
of cell viability induced by calycosin was 36% at 100 mM,
compared to vehicle control. A significant (P,0.05) increase in cell
proliferation was also observed in VEGF-treated cells (77%),
which served as the positive control.
The process of angiogenesis is complex, and typically consists of
proliferation and alignment to form tubular structures [41]. To test
the ability of calycosin to induce HUVEC capillary tube
formation, a Matrigel model was used. When HUVECs were
cultured on Matrigel – a solid gel of mouse basement membrane
proteins – cells aligned easily and formed hollow, tube-like
structures. Fig. 7B shows that a very low level of tube formation
was observed when HUVECs were plated on Matrigel in low-
serum medium, whereas morphological changes were observed
after treatment with calycosin. Quantitative analysis indicates that
calycosin stimulated HUVECs to form more branching points
(Fig. 7B). The number of branching points increased in a dose-
dependent manner and reached its maximum (71%) at a calycosin
concentration of 100 mM. A significant (P,0.05) increase in
branching points was also observed in VEGF-treated cells (71%),
which served as the positive control.
Calycosin induces angiogenesis via activation of MAPK
signaling pathway
ERK1/2, one of the major targets of the MAPK signaling
pathway, has been implicated in the regulation of angiogenesis for
different functions including cell proliferation, migration and
survival [41,42]. To evaluate the rapid activation of these kinases,
western blotting was used to examine the phosphorylation of
ERK1/2 following calycosin treatment.
Firstly, phospho-ERK1/2 and total-ERK1/2 were detected
following treatment with calycosin after different time durations.
Calycosin stimulated the phosphorylation of ERK1/2 in a time-
dependent manner (Fig. 8A–i), which reached a plateau at 30–
60 min, and rapidly declined thereafter. However, the total
protein levels of ERK1/2 remained unaffected throughout the
course of these experiments. Furthermore, phosphorylation of
ERK1/2 in HUVECs was enhanced in a dose-dependent manner
after incubating with different concentrations of calycosin (Fig. 8A–
i). The phosphorylation of ERK1/2 reached its maximum at a
calycosin concentration of 100 mM, consistent with the results of
the XTT assay. These data demonstrate that calycosin stimulated
rapid activation of ERK1/2 in a time- and dose-dependent
manner.
To further confirm the involvement of ERK1/2 in calycosin-
mediated angiogenesis, a specific blocker was applied to examine
its effect on calycosin-induced proliferation. HUVEC proliferation
was significantly (P,0.05) increased after incubating with
calycosin, but this was significantly (P,0.05) inhibited after pre-
treatment with ERK activation inhibitor peptide II (Fig. 8B–i).
Altogether, these results indicate that ERK1/2-dependent path-
ways are involved in calycosin-induced HUVEC proliferation.
Calycosin induces HUVEC proliferation via interaction
with ER
To confirm whether ER is involved in the angiogenic activity of
calycosin, the effects of ER inhibitors on calycosin-induced
Figure 3. Gene expression of calycosin treated zebrafish. Data are expressed as mean 6SEM from three individual experiments. **P,0.01,
#P,0.001 vs control group; P,0.01 vs calycosin group.
doi:10.1371/journal.pone.0011822.g003
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HUVEC proliferation, and ERK1/2 activation, were examined.
Fig. 9A demonstrates that calycosin significantly promoted the
HUVEC proliferation by 67% (P,0.05), while the ER inhibitor
(IVI182, 780) significantly reduced the proliferation by 40%
(P,0.05). Western blotting revealed that expression of phospho-
ERK1/2 was markedly enhanced in calycosin-treated HUVECs,
whereas ICI182, 780 (30 mM) suppressed phosphorylation of
ERK1/2 to control levels (Fig. 9B). Total ERK1/2 protein levels
were unaffected by these treatments. Altogether, these results show
that the effects of calycosin on HUVEC proliferation and ERK1/2
activation could be reversed by ER inhibition.
Discussion
Proliferation of endothelial cells is a key process in angiogenesis
[43]. The present study demonstrates that calycosin enhances
endothelial cells proliferation in HUVECs in vitro, and in zebrafish
embryos in vivo. Both blood vessel diameter and number of
endothelial cells increased following calycosin treatment of
transgenic zebrafish. Thus, these findings suggest that calycosin
possesses pro-angiogenic activity.
Furthermore, these results show that the calycosin-induced
phenotypic change in zebrafish involved activation of angiogene-
sis-related signaling pathways. Changes in mRNA expression levels
of several angiogenesis-specific markers were determined. VEGF,
also known as vascular permeability factor (VPF), was originally
described as an EC-specific mitogen, a potent angiogenic factor
[44], as well as an essential growth factor for vascular ECs.
Formation of new blood vessels is orchestrated by a plenitude of
different proteins, including cell adhesion molecules, ECM
components and VEGFRs. Gene targeting experiments have
provided insights into the functions of VEGFRs [45,46]. Although
inactivation of each individual VEGFR can cause embryonic
lethality at mid-gestation, they have different functions [47,48].
VEGFR2 is the receptor that initiates the main signaling pathways
activated by VEGF. The main function of VEGFR1 appears to be
in regulating binding between VEGF and VEGFR2 [49]. In this
investigation, the results of real-time PCR illustrate that calycosin
Figure 4. The effects of VEGFR tyrosine kinase inhibitor on calycosin-induced angiogenesis in zebrafish embryos. (A) Control: embryo
treated with 0.1% DMSO at 96 hpf. (B) Calycosin: embryo treated with calycosin (100 mM) at 72 hpf for 24 h. (C & E) VRI: embryo treated with low
concentration (100 ng/ml, C) and high concentration (1 mg/ml, E) of VRI at 72 hpf for 24 h. (D) VRI and calycosin: embryo treated with both VRI
(100 ng/ml) and calycosin (100 mM) at 72 hpf for 24 h. (a–e) Enlarged SIV region (64.5) of A–E respectively. (F) Effects of calycosin and/or VRI on the
diameter of SIV compared with the control group. Data are plotted as mean6SEM, (n = 3), #P,0.0001. (G) Effects of calycosin and/or VRI on the
number of endothelial cells in SIV region compared with the control group. Data are plotted as mean6SEM, (n = 3), *P,0.05, #P,0.001.
doi:10.1371/journal.pone.0011822.g004
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extract increased VEGF expression, as well as having a tendency to
upregulate expression of VEGFR1 and VEGFR2. Moreover,
VKRI, an inhibitor of VEGFR1 and VEGFR2, was shown to
potently inhibit the kinase activities of these two proteins [35]. These
data confirmed the predominant involvement of these angiogenesis-
specific targets in calycosin-induced increases in endothelial cell
number and blood vessel diameter at SIVs in zebrafish, and further
supported the hypothesis that these clear phenotypic changes were
as a result of angiogenesis stimulation.
Menopausal women suffer from many health problems such as
hot flushes, sweating and mood swings; they are also more prone
to cardiovascular disease, bone density reduction and osteoporosis.
These problems are mainly due to deficiencies of ovarian
hormones, especially estrogen. Therefore, hormone replacement
therapy (HRT) is often applied to relieve such menopausal
symptoms, and offer protection against osteoporosis and cardio-
vascular diseases [50]. However, recent epidemiological studies,
and randomized trials, have revealed that women who used HRT
had an increased risk of developing breast cancer, strokes and
thromboembolisms [50,51]. These reports contributed to the
development of SERM, which is defined as molecules binding with
ER and producing a change in the biological activities of the
receptor with cell, or tissue, specificity.
Cell-free and cell-based estrogenic assays both revealed that
calycosin competitively bound with ERa and ERb. In addition,
calycosin also displayed selective potency and affinity to ERa and
ERb in reporter-gene assays. Clinical and animal studies have
suggested multiple benefits of SERM, and several SERMs have
already been clinically approved, including raloxifene and
tamoxifen. Recent findings have demonstrated the beneficial
effects of these two classical SERMs upon the vascular system
[52,53,54,55]. Since raloxifene and tamoxifen share the same/
similar antagonistic action with calycosin at ERb, we compared
the angiogenic effects of the three compounds in zebrafish
embryos. Of the three, only calycosin promoted significant
angiogenic development in the SIVs of zebrafish embryos.
A previous study investigated the activities of compounds
demonstrated to be active in zebrafish embryo bioassays, in both
zebrafish and mammalian cell lines [56]. Interestingly, only half
of the 14 compounds were shown to be active in both embryos
and either one of the cell lines, revealing that they exerted direct
action upon cells. In our results, calycosin not only promoted
angiogenesis in zebrafish but also enhanced endothelial cells
proliferation and tube formation in HUVECs in vitro, both of
which are standard tests for angiogenesis. Although no study has
been carried out to identify bioequivalent doses between cell
Figure 5. Cell-free and cell-based estrogenic assays. (A) Dose-response curves for competitive binding assay. Calycosin and 17-b-estradiol (E2)
at the concentrations shown competitively bind with (i) ERa and (ii) ERb, which caused displacement of FluormoneTM ES2 from ER; (B) Dose-response
curves for GeneBLAzer b-lactamase reporter-gene assay. (i) Agonistic activities and (ii) antagonistic activities of calycosin at ERa and ERb were
determined in ERa-UAS-bla GripTiteTM and ERb-UAS-bla GripTiteTM cell lines respectively. Results are presented as mean6SEM. (n$2 independent
experiments), P,0.01 between different ER subtypes followed by two-way ANOVA.
doi:10.1371/journal.pone.0011822.g005
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cultures and zebrafish, our results suggest that calycosin, at least
in part, exerts direct action upon endothelial cells. Thus, we can
further investigate the mechanism of action of calycosin in cell
culture.
Many studies have shown that MAPK signaling pathway
activation plays a vital role in the proliferation, migration and
morphogenesis of endothelial cells induced by pro-angiogenic
factors [57,58]. To further elucidate the mechanism of the
Figure 6. The effects of calycosin, raloxifene and tamoxifen in SIVs of Tg(fli1:EGFP). (A) Controls: were treated with 0.1% DMSO at 96 hpf,
showing no effect on vessel formation (B–E) were treated with 10 mM raloxifene, 3 mM tamoxifen, 10 mM 17-b-Estradiol and 100 mM calycosin at
72 hpf for 24 h. (a–e) Enlarged SIV region (64.5) of A–E respectively. Abnormal phenotype of blood vessel formation in SIVs was indicated by white
arrow, showing slight increase in vessel diameter. Significant increase in vessel diameter was indicated by thick white arrow.
doi:10.1371/journal.pone.0011822.g006
Calycosin is Pro-Angiogenic
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angiogenic activity of calycosin, activation of MAPK signaling was
detected. It was shown that calycosin stimulated ERK1/2
activation rapidly in HUVECs (Fig. 8A). In addition, an ERK1/
2-specific inhibitor effectively reversed calycosin-induced HUVEC
proliferation (Fig. 8B). Thus, these results indicate that calycosin
promotes angiogenesis via activation of MAPK with the
involvement of ERK1/2.
Since calycosin selectively modulates ER transcriptional activa-
tion, as well as promoting angiogenesis, to further elucidate the
relationship between these two activities, the effects of ER inhibitor
ICI182, 780 on calycosin-induced HUVEC proliferation and the
expression of phospho-ERK1/2 were examined. In vitro and in vivo
studies have demonstrated that estrogen and ER agonists promote
angiogenesis in endothelial cells via ERs [3,59]. It has also been
shown that inhibition of ER reduces angiogenesis induced by an ER
agonist [5]. Here, we showed that ICI182, 780 significantly
(P,0.05) decreased calycosin-induced HUVEC proliferation
(Fig. 9A). Moreover, recent studies indicate that 17-b-estradiol
stimulates ERK1/2 phosphorylation through ERa activation in
endothelial cells [60]. In this sense, our data revealed that calycosin-
stimulated ERK1/2 activation was also abrogated by ER inhibition
(Fig. 9B). Altogether, our data suggest that calycosin stimulates
activation of ER and MAPK signaling pathways, which may
contribute to the pro-angiogenic activity of calycosin.
In conclusion, this present study provides evidence that calycosin
from Radix Astragali acts as a novel SERM, since calycosin was
shown to competitively bind with ERa and ERb, as well as
selectively modulate ER transcriptional activities. We also show that
calycosin treatment promotes several features of angiogenesis in
HUVECs in vitro. Our studies elucidate the mechanism of the
angiogenic activity of calycosin on HUVEC cells, where it promotes
angiogenesis through activation of ER and the MAPK signaling
pathway to play multiple roles in regulating cell proliferation and
morphogenesis. Finally, our findings provide inspiration for further
development of Radix Astragali and calycosin as therapeutic agents
for the treatment of problems associated with estrogen deficiency,
such as cardiovascular diseases in post-menopausal women.
Materials and Methods
Ethics Statement
All animal experiments were conducted according to the ethical
guidelines of ICMS, University of Macau and the protocol was
approved by ICMS, University of Macau.
Chemicals and reagents
Kaighn’s modification of Ham’s F12 medium (F-12K), fetal
bovine serum (FBS), phosphate-buffered saline (PBS), charcoal-
stripped fetal bovine serum (CS-FBS), penicillin-streptomycin (PS),
0.25% (w/v) trypsin/1 mM EDTA and nitric oxide indicators
DAF-FM diacetate were all purchased from Invitrogen (Carlsbad,
CA, USA). Endothelial cell growth supplement (ECGS), heparin,
gelatin, ER antagonist ICI182, 780, 17b-estradiol, Raloxifene
hydrochloride, Tamoxifen, SNP and wortannin were supplied by
Sigma (St Louis, MO). Growth factor reduced (GFR) MatrigelTM
basement membrane matrix was obtained from BD Biosciences
(Bedford, MA). ERK activation inhibitor peptide II was obtained
from Biocalchem (Darmstadt, Germany). Vascular endothelial
growth factors (VEGF) were obtained from R&D Systems
(Minneapolis, MN). Anti-p-ERK1/2 antibody, anti-ERK1/2
antibody and goat anti-rabbit IgG HRP-conjugated antibody
were all purchased from Cell Signaling Technology (Berverly,
MA). Dimethyl sulfoxide (DMSO) was acquired from SIGMA and
the calycosin($99%) was extracted at our laboratory. Calycosin
was dissolved in DMSO to form a 100 mM solution. VEGFR
tyrosine kinase inhibitor II (VTKI) was purchased from Calbio-
chem Company/EMD Chemicals Inc (Cat. No. 676481) and was
dissolved in DMSO to form a 1 mg/ml solution.
Maintenance of zebrafish and its embryos
EGFP is expressed in all endothelial cells and each nucleus of
Tg(fli-1:EGFP) and Tg(fli-1:nEGFP) zebrafish embryos. All types of
zebrafish were maintained as described in the Zebrafish Handbook
[61].
Embryo collection and drug treatment
Zebrafish embryos were generated by natural pair-wise mating
(3–12 months old) and were raised at 28.5uC in embyro water.
Healthy, hatched zebrafish were picked out at 3 dpf and
distributed into a 12-well microplate with 10 to 15 fish in each
well. Different concentrations (10, 30, 100 mM) of calycosin,
raloxifene or tamoxifen solutions were then added to wells and
incubated at 28uC for 24 h. Embryos receiving DMSO (0.1%)
served as vehicle controls and were equivalent to no treatment.
Each experiment was repeated at least three times, with 30
embryos per group. VTKI was dissolved in DMSO as stock.
Zebrafish embryos, Tg(fli-1:EGFP) and Tg(fli-1:nEGFP), were
treated with inhibitor dissolved in embryo water from 3 dpf at
the concentration indicated, controlled by DMSO treated
embryos. Embryos were maintained using standard methods.
Morphological observation of zebrafish
At 96 hpf, zebrafish were removed from microplates and
observed for viability and gross morphological changes under a
fluorescence microscope (Olympus IX81 Motorized Inverted
Microscope, Japan) equipped with a digital camera (DP controller,
Soft Imaging System, Olympus). Images were analyzed with
Axiovision 4.2 and Adobe Photoshop 7.0.
Assessment of vascular changes
Three random points in SIVs of Tg(fli1:EGFP) zebrafish
embryos were chosen for vessel diameter measurement using
AxiovisionLE 4.1. Numbers of endothelial cells in SIVs of
Tg(fli1:nEGFP) zebrafish embryos were assessed by direct counting
of the total number of green light points. Each green light point
represents one endothelial cell (GFP+).
Total RNA extraction, reverse transcription, and real-time
PCR
Zebrafish embryos at 72 hpf were treated with calycosin for 6 h.
Total RNA was extracted from 30 zebrafish embryos of each
treatment group using the RNeasy Mini Kit (Qiagen, USA) in
Figure 7. The effects of calycosin on HUVECs in vitro. (A) Effects of calycosin on proliferation of HUVEC by XTT assay. HUVECs were seeded in
96-well plates and incubated with calycosin at different concentrations. Cell proliferation was assessed using XTT assay; (B) Tube formation of
calycosin-treated HUVECs on Matrigel. HUVECs cultured on 3-dimensional Matrigel in treatment of calycosin (3 mM, 10 mM, 30 mM and 100 mM). Cells
receiving 0.1% DMSO served as vehicle control. Number of branching points in different concentrations of calycosin-treated HUVECs was calculated
by computer software (Metamorph). Results are expressed as percentage of control (100%) in mean6SEM (n$3 independent experiments), *P,0.05
versus control.
doi:10.1371/journal.pone.0011822.g007
Calycosin is Pro-Angiogenic
PLoS ONE | www.plosone.org 10 July 2010 | Volume 5 | Issue 7 | e11822
accordance with the manufacturer’s instructions. RNA was reverse
transcribed to single-strand cDNA using SuperScriptTM III First-
Strand Synthesis System for RT–PCR (InvitrogenTM, USA),
followed by real-time PCR using the TaqManH Universal PCR
Master Mix and 250 nM custom TaqMan primers for zebrafish
Flk1A, Flk1B, VEGFR1, VEGFA2 (Applied Biosystems, USA) in
the ABI 7500 Real-Time PCR System (Applied Biosystems). The
expression of Flk1A, VEGFA2 mRNA was normalized to the
amount of bactin1, using the relative quantification method
described by the manufacturer.
The zebrafish bactin1 primers were 59-CAAGATTCCATACC-
CAGGAAGGA-39 (F) and 59-CAAGATTCCATACCCAGGAA-
GGA-39(R) (Applied Biosystems, USA).
The zebrafish Flk1A (kdrl) primers were 59- GACCATAAAA-
CAAGTGAGGCAGAAG-39 (F) and 59- CTCCTGGTTTGA-
CAGAGCGATA-39(R) (Applied Biosystems, USA).
Figure 8. Role of MAPK signaling in calycosin-induced angiogenesis. (A) Effects of calycosin on ERK1/2 activation. HUVEC were incubated
with calycosin (100 mM) at indicated time or with calycosin in different concentrations for 30 min. Expressions of phospho-ERK1/2 and total-ERK1/2
were analyzed by western blotting and quantified by densitometry. The values indicate the relative densitometric units. Results are represented as
mean6SEM (n= 3 independent experiments), * P,0.05 versus control. (B) Effect of ERK activation inhibitor peptide II on calycosin-induced HUVEC
proliferation. HUVECs were pre-treated with 0.5 mM ERK activation inhibitor peptide II (ERK inhibitor II) for 1 h before the addition of calycosin
(100 mM). Changes in HUVEC proliferation were determined 48 h later by XTT assay. 20 ng/ml VEGF was used as the positive control in this
experiment. ‘‘cal’’ is the abbreviation of calycosin. Results are expressed as percentage of vehicle control (100%) in mean6SEM (n$3 independent
experiments), *P,0.05 versus vehicle control, # P,0.05 versus calycosin.
doi:10.1371/journal.pone.0011822.g008
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The zebrafish Flk1B (kdr) primers were 59- CAAGTAA-
CTCGTTTTCTCAACCTAAGC-39 (F) and 59-GGTCTGCTAC-
ACAACGCATTATAAC-39(R) (Applied Biosystems, USA).
The zebrafish FLT1 primers were 59-AACTCACAGAC-
CAGTGAACAAGATC-39 (F) and 59-GCCCTGTAACGTGTG-
CACTAAA-39(R) (Applied Biosystems, USA).
The zebrafish VEGFA2 primers were 59-GATGTGAT-
TCCCTTCATGGATGTGT-39 (F) and 59-GGATACTCCTG-
GATGATGTCTACCA-39 (R) (Applied Biosystems, USA).
HUVEC culture
Human umbilical vein endothelial cells (ATCC, Manassas) were
cultured in F-12K medium with 2 mM L-glutamine, 1.5 g/l
sodium bicarbonate, 100 mg/ml heparin, 30 mg/ml endothelial
cell growth supplement and 10% FBS at 37uC in a humidified
atmosphere of 5% CO2. Tissue culture flasks, 96-well plates and 6-
well plates were pre-coated with 0.1% gelatin. Cells were exposed
to culture medium with 10% CS-FBS instead of normal FBS for at
least 1 day before experiments. Cultures were then starved with
low-serum medium (contain 0.5% CS-FBS) for either 24 h in cell
proliferation assays, or overnight in other assays. All assays were
conducted using low cell passage cells (2–5 passages).
ER fluorescence polarization competitive binding assay
The binding affinity of calycosin to ER-a and b was evaluated
by the commercially available competitor assay (Invitrogen,
Carlasbad, CA) according to the manufacturer’s instructions.
In brief, ER was added to fluorescently tagged ER ligand
(FluormoneTM ES2) to form ER/FluormoneTM ES2 complexes
with a high fluorescent polarization value. Displacement of
fluorescently tagged ligands by unlabeled ligands decreased
fluorescent polarization, resulting in a low value. In this system,
changes in intensity of polarization reflect displacement of
fluorescently tagged ligands. In 96-well plates, serial dilution of
calycosin (1 nM to 36105 nM) or the ER agonist 17-b-estradiol
(104 nM to 1022 nM) were added to ER/FluormoneTM ES2
complexes to compete with ES2 for binding to ER. Plates were
incubated at room temperature for 2 h and fluorescent polariza-
tion values measured using a Multilabel Counter (Perkin Elmer,
Singapore). Results were expressed as percentages of maximum
displacement induced by 17-b-estradiol (10 mM).
Cell-based ER transcriptional response by GeneBLAzer
b-lactamase reporter-gene assay
Assays were preformed by Invitrogen (USA) as described in
literature [62]. Briefly, GeneBLAzer b-lactamase reporter-gene
assays were performed to measure the agonistic or antagonistic
activities of calycosin at ER. For ER agonist activity assay, 4 ml of
a 106serial dilution of 17-b-estratiol served as the control agonist
(starting concentration 10 mM, 3-fold dilute manner), or calycosin
(starting concentration 300 mM, 3-fold dilute manner), was added
to the appropriate wells of a 384-well plate. 32 ml of cell suspension
and 4 ml of Assay Media were added to each well to bring the final
volume to 40 ml. Plates were incubated for 16–24 h, then 8 ml of
1 mM substrate loading solution was added to each well, and plates
incubated for another 2 h at room temperature. For the antagonist
activity assay, cells were grown and prepared as above. 4 ml of a
106serial dilution of 4-hydroxytamoxifen (starting concentration
Figure 9. Role of ER in calycosin-induced angiogenesis. (A) Effects of ICI182, 780 on calycosin-induced HUVEC proliferation. HUVECs were pre-
treated with ICI182, 780 (30 mM) before the addition of calycosin (100 mM). Data are expressed as percentage of vehicle control (100%) in mean6SEM
(n = 3 independent experiments), *P,0.05 versus control,#P,0.05 versus calycosin. (B) Effect of ICI182, 780 on calycosin-induced activation of ERK1/
2. Calycosin-stimulated phosphorylation of ERK1/2 was completely reversed by the absence of ICI182, 780 (30 mM). Expression of phospho-ERK1/2
and total-ERK1/2 was analyzed by western blotting and quantified by densitometry. The values indicate the relative densitometric units of the p-
ERK1/2 bands with the density of the control band set arbitrarily at 1.0. Results are represented as mean6SEM. ‘‘cal’’ and ‘‘ICI’’ are the abbreviations of
calycosin and ICI182, 780 respectively.
doi:10.1371/journal.pone.0011822.g009
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100 nM) for ERa, RU-496 (starting concentration 10 mM) for
ERb or calycosin (starting concentration 300 mM, 3-fold dilute
manner) was added to cells. Cells were pre-incubated with
calycosin and the antagonist control for 30–60 min, then 4 ml of
17-b-estradiol was added to wells at the pre-determined EC80
concentration. Plates were then incubated for another 16–24 h.
8 ml of 1 mM substrate loading solution was added to each well,
and plates incubated for 2 h at room temperature. All results were
measured using a fluorescence plate reader. Results of agonist
activity assays were expressed as percentage activation of the
defined maximum activation induced by 17-b-estradiol (10 mM).
For the antagonist activity assay, inhibition responses were
expressed as percentage inhibition in the presence of EC80
concentration of 17-b-estradiol according to the previous agonist
activity assay.
HUVEC viability by XTT assay
HUVECs were trypsinised and seeded at 104 cells/well in 96-
well gelatin coated plates. After 24 h, complete medium was
removed and renewed with hormone-free low serum (0.5% CS-
FBS) medium, and samples incubated for 24 h in order to starve
HUVECs to achieve a quiescent state. After these pre-incubations,
different concentrations (1 mM-100 mM) of calycosin medium
were replaced. Cells receiving DMSO (0.1%) served as vehicle
controls, and were equivalent to no treatment. For inhibition
assays, HUVECs were pretreated with inhibitors (10 mM ICI182,
780 and 1 mM ERK activation inhibitor peptide II) for 60 min
before addition of calycosin (100 mM). Cells receiving DMSO
(0.1%) served as vehicle control and were equivalent to no
treatment. On the other hand, cells cultured in VEGF (20 ng/ml)
served as positive controls. After 48 h, cell proliferation was
assessed by XTT for 4 h. The spectrophotometrical absorbance of
each well was measured by a Multilabel counter (Perkin Elmer,
Singapore). The wavelength used to measure absorbance of the
formazan product was 490 nm and the reference wavelength was
690 nm. Cell viability data were expressed as percentage of cell
viability calculated.
Tube formation assay on HUVEC
The effect of calycosin on HUVEC differentiation was
examined by in vitro tube formation on Matrigel [63]. Confluent
HUVECs were harvested and diluted (96104 cells) in 500 ml low
serum medium containing 3–100 mM calycosin, which were then
seeded on 1:1 Matrigel (v/v) coated 24-well plates in triplicate at
37uC for 7 h. Cells receiving DMSO (0.1%) served as vehicle
controls, and were equivalent to no treatment. Besides, cells
cultured in 20 ng/ml VEGF served as positive controls (data not
shown). The network-like structures were examined under an
inverted microscope (at 506 magnification). The tube-like
structures were defined as endothelial cord formations that were
connected at both ends. The number of branching points in three
random fields per well was quantified by Metamorph Imaging
Series software.
Western blotting analysis
Cells were treated with 100 mM calycosin for different time
durations (5–120 min) in the time course study. 20 ng/ml VEGF
was used as a positive control while medium with 0.1% DMSO
served as a negative control. To observe dose-dependent effects of
calycosin, 10 mM, 30 mM and 100 mM calycosin were used to treat
HUVECs for 30 min in culture medium. For inhibition assays,
HUVECs were pretreated with 10 mM ICI182, 780 for 60 min
prior to the addition of 100 mM calycosin. Cells were then washed
with PBS and lysed for 30 min on ice with lysis buffer (0.5 M
NaCl, 50 mM Tris, 1 mM EDTA, 0.05% SDS, 0.5% Triton X-
100, 1 mM PMSF, pH 7.4). Cell lysates were centrifuged at
110006g for 20 min at 4uC. Protein concentrations in the
supernatants were measured using the bicinchoninic acid assay
(Pierce, Rockford, IL). Supernatants were electrophoresed on 12%
SDS-PAGE, and transferred to polyvinylidene diuoride (PVDF)
membranes, which were then blocked with 5% non-fat milk.
Immunoblot analysis was undertaken by incubation with anti-p-
ERK1/2 antibody and anti-ERK1/2 antibody at 4uC overnight.
After washing, membranes were incubated for 1 h at room
temperature with horseradish peroxidase-conjugated goat anti-
rabbit IgG. Proteins were detected using an advanced enhanced
ECL system (GE Healthcare, Little Chalfont, Buckinghamshire,
UK). Semi-quantifications were performed with densitometric
analysis by Quantity One software.
Statistical analysis
Data was analyzed with unpaired two-tailed Student’s t-tests or
one-way ANOVA followed by Tukey’s multiple comparison test,
using GraphPad Prism 5.0 software (San Diego, CA). Curve fitting
was carried out using GraphPad Prism 5.0 (nonlinear fit, variable
slope sigmoidal dose-response model). Data were expressed as
mean6SEM from individual experiments. Differences were
considered as significant at P,0.05.
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